Skip to main content

James Crowe Jr.

Initiative seeks to develop therapies to combat Ebola

Sep. 18, 2014—Vanderbilt University researchers have partnered with Mapp Biopharmaceutical Inc. to develop new human antibody therapies for people exposed to the deadly Ebola and Marburg viruses.

Read more


Cutting-edge research to be showcased in May

May. 1, 2014—Potentially “game-changing” research at Vanderbilt University on infectious diseases, population health and health policy will be showcased during two interactive presentations May 15 and May 22. A segment of the Flexner Discovery Lecture Series, the new “Vanderbilt Cutting-edge Discovery” discussions are highlights of recent presentations to the Vanderbilt Biomedical Science Advisory Board, a group of...

Read more


Vanderbilt Vaccine Center joins global task force to address urgent viral threat

Apr. 7, 2014—World Health Day 2014 Shines Spotlight on Mosquito-borne Viral Diseases Chikungunya virus, a vector-borne disease that is quickly spread by mosquitoes and causes victims to suffer severe fever and pain, has reached the Caribbean and South America—and is predicted to soon cause outbreaks in the United States. For many years the virus has remained primarily...

Read more


Multi-center effort targets lethal Ebola, Marburg viruses

Mar. 6, 2014—Vanderbilt University researchers are collaborating in a multi-center, federally-funded project to develop ways to treat and prevent the highly lethal Ebola and Marburg virus infections.

Read more


Discovery may pave way for RSV vaccine

Feb. 5, 2014—Vanderbilt University scientists have contributed to a major finding, reported this week in the journal Nature, which could lead to the first effective vaccine against respiratory syncytial virus (RSV), a significant cause of infant mortality.

Read more


Nine faculty honored with endowed chairs

Jan. 24, 2014—Nine Vanderbilt University faculty members named to endowed chairs were honored for their academic achievements during a celebration Jan. 22 at the Student Life Center.

Read more


Vaccine researchers ready as new flu strain evolves

Aug. 22, 2013—A worrisome new avian influenza virus, called H7N9, emerged this spring in Eastern China.

Read more


VU researchers ‘goldsmith’ new RSV vaccine approach

Jul. 18, 2013—Vanderbilt vaccine researchers are using gold nanotechnology to develop a new approach to making vaccines.

Read more


Structural snapshot hints at new influenza approach

Feb. 21, 2013—A careful look at how the body’s natural defenses disarm virulent strains of influenza hints at the possibility of a way to fight the flu.

Read more


Targeting post-transplant diabetes

Apr. 12, 2012—Targeting diabetes that develops after a stem cell transplant may help moderate graft-vs.-host disease, an adverse effect of the procedure, and improve outcomes.

Read more


On the tail of RSV infection mechanism

Feb. 15, 2012—New details about the life cycle of respiratory syncytial virus (RSV) could aid the development of therapies to combat this leading cause of serious illness in infants and the elderly.

Read more


Diversity key in antibody repertoire

Oct. 7, 2011—Antibodies to the 2009 H1N1 influenza strain reveal new insights into how antibody diversity forms and functions, with possible implications for designing flu vaccines.

Read more


VIEW MORE EVENTS >